Liuyun Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liuyun Wu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Lizhu Han
Affiliation Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
2 shared publicationsQinan Yin
Affiliation Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
2 shared publications- Yuan Bian
Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China
2 shared publications - Fengjiao Kang
Affiliations Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Pharmacy Department of Xinjiang Medical University Affiliated Traditional Chinese Medicine Hospital, Urumqi Xinjiang, China
1 shared publication Fengqun Cai
Affiliation Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
1 shared publication- Lan Bai
Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342548
Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
Fondaparinux is a widely used anticoagulant for treating venous thromboembolism and acute coronary syndrome by inhibiting factor Xa. However, it carries a risk of bleeding. This study analyzes its safety using the FDA Adverse Event Reporting System (FAERS) database to guide clinical use and future research. Data from 2004 Q1 to 2024 Q3 were examined using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) methods. Among 21,483,491 reports, 5,788 were related to fondaparinux, with 17,523 adverse events (AEs). The most affected systems were vascular (n = 2046) and blood/lymphatic (n = 1125). Abnormal coagulation factor X concentration, thrombosis with thrombocytopenia syndrome, and incision site hematoma had the strongest signals. AEs were more frequent in females and elderly patients, especially within the first month. Additional Preferred Term (PT)–level signals defined in MedDRA were observed, including heparin induced thrombocytopenia and eosinophilia. Heightened pharmacovigilance particularly in older adults may be warranted. This study enhances understanding of fondaparinux’s safety, providing insights for reducing risks and ensuring safer clinical application.
- 11 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342548
Open AccessDisproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
Fondaparinux is a widely used anticoagulant for treating venous thromboembolism and acute coronary syndrome by inhibiting factor Xa. However, it carries a risk of bleeding. This study analyzes its safety using the FDA Adverse Event Reporting System (FAERS) database to guide clinical use and future research. Data from 2004 Q1 to 2024 Q3 were examined using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) methods. Among 21,483,491 reports, 5,788 were related to fondaparinux, with 17,523 adverse events (AEs). The most affected systems were vascular (n = 2046) and blood/lymphatic (n = 1125). Abnormal coagulation factor X concentration, thrombosis with thrombocytopenia syndrome, and incision site hematoma had the strongest signals. AEs were more frequent in females and elderly patients, especially within the first month. Additional Preferred Term (PT)–level signals defined in MedDRA were observed, including heparin induced thrombocytopenia and eosinophilia. Heightened pharmacovigilance particularly in older adults may be warranted. This study enhances understanding of fondaparinux’s safety, providing insights for reducing risks and ensuring safer clinical application.
- 6 March 2024
- Published by Elsevier in Phytomedicine
- Vol. 128, 155505
A promising therapy for fatty liver disease: PCSK9 inhibitors
- 6 March 2024
- Published by Elsevier in Phytomedicine
- Vol. 128, 155505
A promising therapy for fatty liver disease: PCSK9 inhibitors